Tumours display an astonishing variation in the spatial distribution, composition and
activation state of immune cells, which impacts their progression and response to …

Myeloid cells are pivotal within the immunosuppressive tumour microenvironment. The
accumulation of tumour-modified myeloid cells derived from monocytes or neutrophils …

NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Non–Small Cell
Lung Cancer (NSCLC) provide recommended management for patients with NSCLC …

Abstract Neoadjuvant ipilimumab+ nivolumab (Ipi+ Nivo) and nivolumab+ chemotherapy
(Nivo+ CT) induce greater pathologic response rates than CT alone in patients with …

Despite being the most frequently altered oncogenic protein in solid tumours, KRAS has
historically been considered 'undruggable'owing to a lack of pharmacologically targetable …

Immunotherapy is used to treat almost all patients with advanced non-small cell lung cancer
(NSCLC); however, identifying robust predictive biomarkers remains challenging. Here we …

Worldwide, lung cancer is the most common cause of cancer-related deaths. Molecular
targeted therapies and immunotherapies for non-small-cell lung cancer (NSCLC) have …

Inhibitors of the programmed cell death-1 (PD-1/PD-L1) signaling axis are approved to treat
non-small cell lung cancer (NSCLC) patients, based on their significant overall survival (OS) …

Hepatocellular carcinoma (HCC) is a prevalent disease with a progression that is modulated
by the immune system. Systemic therapy is used in the advanced stage and until 2017 …

Abstract Anti-PD-1/PD-L1 agents have transformed the treatment landscape of advanced
non-small cell lung cancer (NSCLC). To expand our understanding of the molecular features …